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BARRIERS AND FACILITORS OF HEALTHCARE USE AMONG PEOPLE WHO 
INJECT DRUGS  
 
Hepatitis C Virus (HCV) is an infection that can have grave consequences when 
left untreated. Hepatitis C can be easily eradicated with direct acting antiviral therapy. 
People who inject drugs (PWID) and inmates are among those with the highest incidence 
of HCV. However, cure rates among this population remains low. This is, in part, related 
to an interruption in the HCV care cascade such that only 30% of PWID are linked to 
care and only 8% of those receive treatment. Inadequate screening and failure to be 
linked to HCV care remain the largest impediments to treatment success. There is limited 
research on barriers and facilitators to primary care, where screening may take place, and 
linkage to HCV care among PWID. Few studies have evaluated vulnerable populations 
such as those living in rural communities or inmates.   
The purpose of this dissertation was to develop a broader understanding of 
barriers and facilitators to healthcare utilization among PWID at the primary care and 
specialist levels (linkage to care). Three manuscripts addressed important gaps in 
knowledge. The first was a review of the literature to describe the state of science on 
linkage to care among PWID. All but one reviewed study recruited from countries with 
universal healthcare, urban areas, and opioid substitution facilities.  The review of the 
literature revealed that little is known about the barriers/facilitators to linkage to HCV 
care faced by rural-dwelling PWID from countries without universal healthcare.  
The second manuscript is a study to determine whether predictors of linkage to 
care identified in urban-dwelling PWID from countries with universal healthcare 
predicted seeking HCV care among PWID living in rural Appalachia. Data were obtained 
from a subsample of 63 HCV positive PWID who recently used opioids, were between 
the ages of 18-35 years, and lived in one of five rural counties in Kentucky. Logistic 
regression revealed that recent injection drug use was the only predictor of seeking HCV 
care. However, remote use of opioid substitution therapy and no transportation issues 
approached clinical significance.  
Although not evaluated in our second manuscript, seeing a primary care provider 
(PCP) is associated with an increased likelihood of being linked to care and higher rates 
of screening/diagnosis. Among rural dwelling PWID, there are subpopulations that may 
face unique barriers to linkage to care. One sub-population that may be particularly 
 
     
 
vulnerable are female PWID who are incarcerated. Therefore, the purpose of the third 
study was to determine predictors of primary care use using data from 302 female 
inmates from rural Appalachia with a history of injecting drugs. Age, insurance issues, 
and health problems that interfere with responsibilities were predictors of PCP use.  
In this dissertation, I have addressed important gaps in the literature by 
determining barriers and facilitators to seeking HCV care and primary care use among 
PWID from rural Kentucky. Additional studies are needed using a larger sample of rural 
PWID to confirm our findings. In addition, further studies should evaluate system and 
provider level barriers to linkage to care and PCP use among rural PWID. 
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CHAPTER 1.  INTRODUCTION 
1.1  An overview of hepatitis C virus 
Hepatitis C virus (HCV), a blood-borne viral infection, is a national health 
concern with high prevalence and incidence rates. There are approximately 2.4 million 
persons living with chronic HCV in the United States (U.S.).1 In 2016, an estimated 
41,200 new acute cases of hepatitis C were diagnosed.2 Injection drug use remains the 
leading cause of HCV in the U.S. with an estimated 53% of people who inject drugs 
(PWID) infected with HCV.3 Thus, examining ways to improve injection drug use 
treatment can enhance our understanding of ways to curb the high rates of HCV in the 
U.S.  
Left untreated, HCV can have serious consequences including porphyria, 
glomerular nephritis, cryoglobulinemia, cirrhosis, hepatocellular carcinoma, and 
subsequent death.4 In 2007 alone, there were 15,106 deaths related to HCV, surpassing 
deaths associated with human immunodeficiency virus (HIV) in the U.S.3,6 Up to one 
fifth of persons with chronic HCV infection develop cirrhosis, making HCV the principal 
reason for liver transplantation in the U.S.3,5 The morbidity and mortality rates due to 
untreated chronic HCV infection are expected to climb over the next few decades, 
resulting in 1.76 million persons developing cirrhosis, 1 million dying of HCV-related 
complications, and 400,000 developing hepatocellular carcinoma.7An estimated 1-5% of 
persons with chronic HCV will die from cirrhosis or hepatocellular carcinoma.3 HCV-
related morbidity and mortality can be prevented with prompt curative treatment, yet less 
than 10% of persons with chronic HCV infections receive treatment. Therefore, it is 
crucial to address barriers and optimize access to evidence-based treatments among those 




1.2 Hepatitis C virus care cascade 
The cascade of care, or care continuum, is a framework originally designed for 
persons with HIV, but has been also applied to persons with HCV.8 -10 While there is no 
universal consensus on defintion,8 the World Health Organization defines the HCV care 
continuum as progression through screening/diagnosis, treatment, cure, to chronic post-
treatment care as needed.11 At least seven stages have been identified: (1) being infected 
with HCV; (2) screening for HCV antibody and being made aware of infection status; (3) 
accessing specialty care; (4) receiving confirmatory HCV RNA test; (5) undergoing 
fibrosis assessment; (6) being prescribed HCV treatment; and (7) achieving a sustained 
virologic response (SVR) or cure.4 An eighth stage has been proposed- prevention of 
reinfection in high-risk groups after being cured.12  Alternatively, the Infectious Disease 
Society of America and the American Association for the Study of Liver Diseases use a 
simplified framework of three major time points: screening, linkage-to-care, and 
treatment uptake.13 Based on this simplified framework, screening is the process by 
which at risk persons are identified and tested for HCV antibodies followed by 
confirmatory testing with nucleic acid test (i.e. HCV RNA), when appropriate;13 linkage-
to-care is the process by which patients are evaluated by a practitioner who can manage 
and treat HCV infection; and treatment uptake is the process of receiving HCV 
treatment.13-14  
Although PWID are at the highest risk for contracting HCV, they are the least 
likely to be cured. An examination of a cross-sectional surveillance system of 2,222 
PWID in Australia found that 89% had received HCV antibody testing in their lifetime of 
which 57% tested positive.4 Nearly half of those who tested positive for HCV antibodies, 




had detectable HCV RNA, but, unfortunately, only 31% were linked-to-care an HCV 
specialist.4 Among those linked to care, 8% received treatment, and 3% achieved a cure.4 
Hence, despite the availability of highly effective antiviral therapy, cure rates remain low 
among PWID; which, in part, may be attributed to a breakdown in progression through 
the HCV care cascade. 
Fundamentally, appropriate screening, diagnosis (being made aware of having 
HCV), and referral to a healthcare specialist are necessary for successful treatment. 
Primary care providers (PCP’s), are well positioned to screen, diagnose, and refer 
patients to a HCV specialist. In fact, people who follow with a PCP are nearly four times 
as likely to be assessed by a HCV specialist (linked to care).15 Unfortunately, PWID 
underutilize primary care services; this is more pronounced in rural communities.3, 6  
Underutilization of PCP services is an important factor which compromises 
proper care for PWID. Even less is known about barriers/facilitators to PCP use among 
rural-dwelling PWID. Moreover, to my knowledge, there are no published reviews of the 
literature or meta-analysis on linkage to HCV care among PWID. Most research on 
linkage to care among PWID has been conducted in urban areas and in countries with 
universal healthcare. Therefore, the purpose of this dissertation was to develop a broader 
understanding of the barriers and facilitators to healthcare utilization among rural-
dwelling PWID at the primary care level (screening) and at the specialist level (linkage to 
care).  
The subsequent chapters of this dissertation represent the foundation of my 
program of research. First, a review of the literature was performed to establish the state 




of the studies, participants were recruited from urban areas and in countries with 
universal healthcare. Subsequently, a secondary data analysis was conducted to determine 
if barriers/facilitators to seeking HCV care in rural-dwelling PWID in the US were 
similar to those among urban-dwelling PWID from countries with universal healthcare. 
Finally, because primary care use is a crucial first step to being screened and referred to a 
HCV specialist, we conducted a secondary data analysis to determine predictors of 
primary care use among rural-dwelling PWID.  
1.3  Summary of subsequent chapters 
Chapter Two is a review of the literature to determine barriers and facilitators 
associated with linkage to HCV care among PWID. PubMed, Ovid, CINHAL, 
MEDLINE, and PsychINFO were searched using the following terms: access, HCV care 
continuum, HCV care cascade, barriers, facilitators, factors, injection drug use, linkage-
to-care, treatment evaluation, and hepatitis C. Given the limited research on this topic, no 
time constraint on publication date was imposed. Twenty-three of the 134 articles 
identified during the initial searches met inclusion criteria and were reviewed. Articles 
were excluded if the majority of the sample was not PWID or the majority were co-
infected with HIV. Seven articles met selection criteria. In all but one reviewed study, 
participants were from large urban cities, in countries with universal health care, and 
from addiction clinics. Little is known about factors associated with linkage to care in 
rural-dwelling PWID who likely have less access to care and fewer resources. 
Chapter Three is a secondary data analysis of PWID living in rural Appalachia. 
The purpose of the study was to determine whether factors identified in urban 




parent study, data were collected using an online survey from 249 people who use drugs, 
aged 18-35 years, who reported living in one of five rural counties in Appalachian 
Kentucky, and using opioids in the last 30 days.  We described the progression through 
the HCV care cascade for the 115 participants that reported a history of injecting drugs. 
Sixty-three of those PWID, reported testing positive for HCV antibodies. Logistic 
regression was run using data from these 63 participants, to determine if child caregiver 
status, recent injection drug use, transportation issues, homelessness, and the absence of 
criminal issues were predictors of linkage to care (operationally defined as self-report of 
seeking treatment for HCV).     
Seeing a PCP is associated with a lower risk of infection and an increased 
likelihood of being screened and linked to HCV care.15-17 Therefore, we examined 
existing literature to determine what is known about barriers/facilitators of PCP use 
among PWID and found that little is known about this topic. Furthermore, to our 
knowledge, none of the published studies had an exclusive sample of rural dwelling or 
incarcerated PWID. Therefore, Chapter Four is a secondary data analysis to determine 
predictors of PCP use among incarcerated female PWID living in rural Appalachia. Data 
were selected from the 302 participants who reported a history of injecting drugs from a 
larger randomized control trial. Anderson’s Behavioral Model of Health Services Use 
was used as a framework to identify independent predictors of PCP use from 
predisposing factors, potential enabling factors, and healthcare needs.  Multivariate 
logistic regression analyses, using data from the 302 PWID, were used to determine 




Chapter Five is a synthesis of the results from Chapters 2, 3, and 4 in reference to 




CHAPTER 2. BARRIERS AND FACILIATORS TO LIKNAGE TO CARE: A REVIEW 
OF THE LITERATURE 
Abstract 
BACKGROUND: Hepatitis C virus (HCV), a blood-borne viral infection, 
disproportionately affects people who inject drugs (PWID). However, PWID are the least 
likely to receive HCV treatment due to difficulty navigating the HCV care continuum. 
PURPOSE: Conduct a review of literature to describe the state of science on barriers and 
facilitators associated with linkage-to-care among PWID. METHOD: PubMed, Ovid, 
CINHAL, MEDLINE and PsychINFO searches using the following terms: HCV care 
continuum, HCV care cascade, barriers, facilitators, factors, injection drug use, linkage-
to-care, and hepatitis C.  RESULTS: Seven articles met selection criteria. Barriers to 
linkage-to-care at the patient-level included ongoing substance use, limited knowledge or 
understanding to make an informed decision, competing priorities, and symptoms. 
Provider-level facilitators included clinical manifestations (i.e. elevated liver enzymes 
and diagnosis of cirrhosis) and a trusting patient-provider relationship. Distance traveled, 
lack of transportation, forgetting appointments, and early appointment times were 
system-level barriers to linkage-to-care. Barriers and facilitators are most frequently 
assessed in urban-dwelling PWID.  Little is known about barriers faced by their rural 
counterparts. DISCUSSION: Future research should be dedicated to exploring the 







Hepatitis C virus (HCV) disproportionately affects persons who inject drugs 
(PWID) with an estimated 30% of PWID between 18-30 years old infected with chronic 
HCV.1 HCV infection can easily be eradicated with treatment success rates approaching 
100%.2 In spite of advancements in antiviral therapy, the percentage of PWID who are 
cured remains low.3,4  
Successful treatment requires progression through a three step HCV care cascade: 
(1) screening, (2) linkage-to-care and (3) treatment uptake.4 Screening is the process of 
testing at risk persons for HCV antibodies and nucleic acid test (when appropriate) and 
then making him/her aware of their status.4 Linkage-to-care is the process of being 
evaluated by a HCV specialist and treatment uptake is the process of taking prescribed 
treatment.4 However, successful treatment is rarely achieved, as most people are lost 
along the care cascade. In a large cross-sectional study of PWID, an estimated 31% of 
those with an active infection were linked to care, 8% were treated, and 3% were cured.3 
The largest dropout occurred between diagnosis and linkage-to-care with a nearly 70% 
attrition rate occurring after screening and diagnosis.3  
PWID are disproportionately burdened with complex social, medical, and 
psychiatric co-morbidities that generate difficulties navigating the HCV care continuum.5 
A better understanding of factors that affect linkage to care is needed to improve cure 
rates. Therefore, the purpose of this review was to describe the state of the science 





2.2.1 Search Strategy and Selection Criteria 
PubMed, Ovid, CINHAL, MEDLINE and PsychINFO databases were searched 
using a combination of the following search terms: access, HCV care continuum, HCV 
care cascade, barriers, facilitators, factors, injection drug use, linkage-to-care, treatment 
evaluation, and hepatitis C. No time constraint was enforced given the limited available 
literature. Article reference lists were examined for additional relevant studies. Articles 
were included if they were from peer-review journal articles, published in English, and 
examined barriers/facilitators to linkage-to-care. Articles were excluded if less than half 
of the sample were not injection drug users and if all participants were co-infected with 
human immunodeficiency virus (HIV). 
The initial search yielded 134 articles. The titles of all 134 articles were reviewed 
for relevance. A total of 106 articles were either duplicates or did not evaluate linkage-to-
care. The abstracts of the remaining 28 were reviewed. Five additional studies were 
eliminated because they did not include barriers/facilitators to linkage-to-care. Among 
the remaining 23 articles, 17 were eliminated because the majority of the population did 
not have a history of injection drug use, or the sample was almost exclusively co-infected 
with HIV. Six articles met inclusion and exclusion criteria. Review of reference lists 
yielded one additional study. No meta-analyses on linkage to HCV care among PWID  
 
2.2.2 Data Extraction 
Components of the study of interest were extracted and organized in a chart (see 
Table 1). Barriers and facilitators were categorized according to three levels- patient, 




such as race, education or socioeconomic status. Provider-level barriers included a 
healthcare provider’s knowledge, bedside manner or experience with a specific 
population and/or condition. System-level barriers are those that occur because of the 
infrastructure or design of the healthcare system. For example, the distance between 
one’s home and the nearest doctor’s office. Some barriers and facilitators could be 
conceived as fitting multiple levels. In these cases, the level was determine based on a 
consensus among authors.  
Barriers and facilitators were further grouped under themes. At the patient level 
they were grouped under: drug use, patient symptoms, HCV knowledge, fear, and social 
factors. At the provider level they were grouped under: clinical findings and patient-
provider relationship. At the system-level, barriers and facilitators were grouped together 
as there were not enough variations to develop themes. Variables that were not predictors 
of linkage-to-care were not included in the results.   
2.2.3 Quality Assessment 
Quantitative studies were assessed for bias using the Scottish Intercollegiate 
Guidelines Network (SIGN) (Table 2).6 The SIGN is used to rank the quality of studies 
as high, acceptable or low using a 10-item checklist with the following domains: subject 
selection, methodology, confounding variables, and statistical analysis.6 SIGN is 
recommended for critiquing cohort studies.6 Qualitative studies were assessed for bias 
using the Critical Appraisal Skills Programme (CASP) Check List (Table 3).7 The CASP 
is a 10 question check list that evaluates the rigor of methodology, validity of the results, 
and the value of the study findings on the local community.7 There are no scoring 




readers and disagreement was resolved with a third reader. Overall, bias was relatively 
low (Tables 2 and 3).  
2.3 Results 
Two studies were qualitative,8-9 four were quantitative (two cross-sectional and 
two cohort studies) 10-13 and one was mixed methods.13 Four studies were conducted in 
Australia,8,10-11, 14 two in Ireland 9, 13 and one in Greece.12 In all seven studies, patients 
were recruited from addiction-based clinics or community service facilities. Only two 
studies were conducted after direct acting antiviral therapy became standard of care.12, 13  
2.3.1 Patient Level 
2.3.1.1 Drug Use 
On-going and recent drug use emerged as a barrier to linkage-to-care in four of 
the seven reviewed articles.9-10, 13, 14 Continued substance abuse including injection drug 
use and alcohol use were associated with poor attendance to consultation with a HCV 
specialist.13, 9 In a cross-sectional study, participants who were receiving Opioid 
Substitution Treatment (OST) or reported injecting drugs in the last 6 months were less 
likely to report having been evaluated by a HCV specialist.14 Conversely, persons who 
had not injected drugs in the last six months were more likely to attend specialty 
consultation.10 None of the authors suggested reasons for why ongoing drug use was a 
barrier. Potential reasons could include lack of referral, which is a provider-level barrier 
or persons who have recent or ongoing drug use may not be willing/able to prioritize 




believe that they must be sober for a specified amount of time prior to being treatment 
eligible and, therefore, do not attend their consultation visit—also a patient-level barrier.   
2.3.1.2 Lack of Symptoms 
HCV infection is often asymptomatic. Being asymptomatic or the perception of 
being physically well, is associated with low rates of engagement with treatment services. 
8-9, 11 Participants in a qualitative study reported that being asymptomatic or feeling well 
was a reason for not seeking care while a decline in physical health or presence of 
symptoms attributed to HCV was a motivator for seeking care.9 In contrast, participants 
with HCV-related symptoms were more likely to have seen a HCV specialist.11 While it 
was not possible to determine if this was attributed to provider referral or an individual 
seeking treatment, it is clear that the presence or absence of symptoms was an important 
factor in treatment engagement. 
2.3.1.3 HCV Knowledge 
HCV-related knowledge was noted to be a facilitator in three of the seven 
articles.8-9, 14 Greater HCV knowledge (transmission, treatment options) and an 
understanding of the potential severity of untreated HCV were associated with a higher 
likelihood of being linked-to-care.8-9, 14 In contrast, a lack of knowledge about the 
diagnosis, the required workup, and treatment options emerged as barriers to seeking 
care.9 
2.3.1.4 Fear 
Fear also served as both a patient-level barrier and facilitator. Specifically, fears 




self-injecting PEGylated Interferon were barriers.8-9, 13 Surprisingly, one of these studies13 
was conducted after DAA therapy which is known for fewer side effects. In addition, 
persons who reported hearing positive accounts from those who received HCV treatment 
(and therefore had less fear) were more likely to receive HCV care.8-9 Persons who 
witnessed friends become ill, require liver transplant or die related to HCV were more 
likely to be engaged in specialty care.8-9 Thus, patients’ specific fears can either increase 
or decrease the likelihood of seeing a HCV specialist.  
2.3.1.5 Social Factors 
Social factors were identified as barriers to linkage-to-care in four of the studies.8-
9, 11, 13 In an observational cohort study in which participants were asked to complete a 
six-item questionnaire on social functioning (financial problems, conflict with partner, 
spouse, relatives or employer, and living with drug users), lower social functioning scores 
were associated with lower likelihood of attending scheduled consultation with a HCV 
specialist.11 Additional competing identified social factors included pending court cases 
(i.e. custodial sentencing), employment obligations, poor financial status, and 
responsibilities for children.8-9, 11, 13  PWID have complex social circumstances which 
influence their ability to be linked to care. 
2.3.2 Provider Level 
Provider-level barriers and facilitators to linkage-to-care were addressed in less 
than half of the reviewed studies. Two major themes were identified as important: clinical 





2.3.2.1 Clinical Findings 
Clinical findings included findings from laboratory values or diagnostic imaging. 
In the reviewed studies, participants with elevated liver enzymes or a prior diagnosis of 
cirrhosis were  more likely to attend initial consultation appointment as compared to 
participants without such complications.10, 14 However, it cannot be ascertained if these 
persons were more likely to be referred to a specialist by a provider based on their 
findings/assessment or if the patients were more likely to attend referral since they were 
aware of this information.  
2.3.2.2 Patient-provider Relationship 
In a qualitative study, participants were asked to identify factors that facilitate or 
inhibit linkage-to-care.9 Participants emphasized the importance of having continuity of 
care. 9 Seeing the same provider created a comfortable environment which in turn 
supported their engagement in care. 9 Another important facilitator was believing that the 
provider was genuinely concerned about their well-being. 9 Participants also identified 
having trust and confidence in their provider as an important influential factor. 9 
Specifically, participants needed to be confident that their provider had adequate 
knowledge about hepatitis C. 9 Conversely, participants who felt that their provider was 
impersonal or distant, were less likely to engage in HCV care. 9 Lastly, participants 
reported feeling stigmatized as a barrier to seeking care. 9 If the participant felt that their 




HCV care.9 Verbal and non-verbal communication from providers has the ability to 
facilitate or impede linkage-to-care.  
2.3.3 System Level 
System-level barriers/facilitators to linkage-to-care were identified in three 
studies.9, 12-13 In a qualitative study, participants identified forgetting appointment 
dates/times which they attributed to the length of time between making the appointment 
and the actual appointment date, and a lack of appointment reminders as barriers to 
attending consultation appointment.9 Other barriers included lack of transportation, long 
distance to nearest HCV specialist, and appointment times early in the day.12-13 
2.4 State of the Science 
There are several limitations with the reviewed literature and gaps in the 
knowledge. First, there is an overall lack of knowledge about barriers and facilitators of 
linkage to care among PWID with HCV. There were only seven studies that met 
inclusion criteria with nearly 40% being qualitative data. Most of the quantitative studies 
were cross-sectional. Only one study examined longitudinal data over 2-5 years.10 
Barriers to linkage to care at one time point may not predict linkage to care over the years 
to come; barriers and facilitators may evolve over time. Moreover, provider- and system-
level barriers were only reported in three articles. It is unlikely that all provider- and 
system-level barriers have been identified.  
 The results of these studies have limited generalizability as the majority (all but 
one) 8 recruited participants from urban cities, countries with universal healthcare, and 




facilities. These participants likely have better access to resources and system-level 
engagement than PWID who reside in rural areas, countries with a multi-payer healthcare 
system, and third-world countries, or are not engaged in addiction treatment.  Predictors 
of being evaluated by PCP for HCV among rural-dwelling PWID were reported in only 
study in the United States.11 These findings suggest similarities in predictors of seeing a 
PCP for hepatitis C infection as urban populations.11 However, further research is needed 
to confirm the generalizability of such findings to rural populations.  
The recruitment sites for three studies employed staff with the intent of increasing 
engagement in HCV specific services.10-11, 13  In one study specifically, all participants 
who failed to attend their specialty appointment were given another appointment and 
offered additional support aimed at increasing linkage to care.10  Participants in the other 
two studies were recruited from facilities that offered on-site hepatitis C treatment 
facilities. 11, 13 This is not standard of practice in most clinics in the U.S., which also limits 
generalizability.    
Barriers related to fear of side effects treatment and knowledge may be less 
relevant. Only two studies were conducted after direct-acting antiviral (DAA) therapy 
became standard of care.12, 13 Interferon-based therapy was notorious for debilitating side-
effects and low cure rates whereas DAA therapy is known for fewer side effects and 
higher efficacy.2 It is likely that fear of side effects, concerns about efficacy, and being 
aware of others negative treatment experiences are less significant today. Likewise, DAA 
therapy has been widely advertised, which provided public education about treatment and 
HCV. Therefore, a lack of knowledge about treatment availability may also be less 




Lastly, linkage to care was operationally defined differently in each study. 
Definitions ranged from objective measures such as documented referral and attendance 
to specialist consultation10-11 or engagement in treatment services13 to self-report 
measures such as “have you ever gone to see a specialist about your HCV?”9 Refer to 
Table 1 for more details. This variation could explain differences in the 
barriers/facilitators found in each study and limits comparisons across studies.  
2.5 Conclusion 
Little is known about the barriers and facilitators to linkage to care among PWID. 
In particular with respect to vulnerable populations such as those living in rural 
environments and in countries without universal healthcare. Future research should focus 
on filling the above identified gaps in knowledge and advancing the state of the science. 
Specifically, longitudinal data that focuses on vulnerable populations with high rates of 
infections such as those residing in rural areas and former/current inmates. Ideally, a 
large observational study should be conducted following rural PWID that test positive for 
HCV antibodies in their natural environment (not recruited only from addiction clinics or 
community resource facilities) over several years to determine predictors of linkage to 
care. In addition, future research should focus on provider- and system-level barriers as 
this is likely more pronounced in rural communities. More current research is also needed 
in the new DAA treatment era to determine if fear of side effects or the ineffectiveness of 
treatment is still relevant. Lastly, future studies should attempt to obtain more objective 
predictor variables as opposed to relying on self-report measures and consistency should 
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Table 2.2: Scottish Intercollegiate Guidelines Network Cohort Check List 
 Fortier Islam Souliotis Grebely 
The study addresses an appropriate 
and clearly focused question.  
Yes Yes Yes Yes 
The two groups being studied are 
selected from source populations that 
are comparable in all respects other 
than the factor under investigation. 
Yes Yes Yes Yes 
The study indicates how many of the 
people asked to take part did so in 
each of the groups being studied.  
No No Yes Yes 
The likelihood that some eligible 
subjects might have the outcome at 
the time of enrolment is assessed and 
taken into account in the analysis.  
N/A N/A N/A N/A 
What percentage of individuals or 
clusters recruited into each arm of the 










Comparison is made between full 
participants and those lost to follow 
up, by exposure status. 
No No No No 
The outcomes are clearly defined. Yes Yes Yes Yes 
The assessment of outcome is made 
blind to exposure status. (If the study 




N/A N/A Unable to 
determine 
Where blinding was not possible, 
there is some recognition that 
knowledge of exposure status could 
have influenced the assessment of 
outcome. 





Table 2.2 (Continued) 
The method of assessment of 
exposure is reliable. 
Yes Yes Yes Yes 
Evidence from other sources is used 
to demonstrate that the method of 
outcome assessment is valid and 
reliable. 
No No Yes No 
Exposure level or prognostic factor is 
assessed more than once. 
No No No No 
The main potential confounders are 
identified and taken into account in 





No Unable to 
determine 
Have confidence intervals been 
provided? 
Yes Yes No Yes 
How well was the study done to 
minimize the risk of bias or 
confounding? 
Acceptable Acceptable Acceptable Acceptable 
Taking into account clinical 
considerations, your evaluation of the 
methodology used, and the statistical 
power of the study, do you think there 
is clear evidence of an association 
between exposure and outcome? 






Table 2.3 Critical Appraisal Skills Programme Check List 
 Treloar Swan Crowley 
Was there a clear 
statement of aims of 
the research? 
Yes Yes Yes 
Is a qualitative 
methodology 
appropriate? 
Yes Yes Yes 
Was the research 
design appropriate to 
address the aims of 
the research? 
Yes Yes Yes 
Was the recruitment 
strategy appropriate to 
the aims of the 
research? 
Yes Yes Yes 
Was the data collected 
in a way that 
addressed the research 
issue? 
Yes Yes Yes 
Has the relationship 
between researcher 
and participants been 
adequately 
considered? 
No No Yes 
Have ethical issues 
been taken into 
consideration? 
Yes Yes Yes 
Was the data analysis 
sufficiently rigorous? 
Yes Yes No 
Is there a clear 
statement of findings? 
Yes Yes No 
How valuable is the 
research? 
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CHAPTER 3.  PREDICTORS OF SEEKING HEPATITIS C CARE AMONG PEOPLE 
WHO INJECT DRUGS LIVING IN RURAL KENTUCKY 
Abstract 
Background: An estimated 3% of persons who inject drugs (PWID) with hepatitis 
C virus (HCV) will progress through the care cascade and be cured. This is due, in part, 
to challenges in being linked to HCV care. Several barriers to linkage to HCV care 
among PWID have been identified, but there are limited studies in rural inhabitants.  
Purpose: To determine whether the factors associated with linkage to care in urban areas 
predict seeking HCV care among PWID with HCV in rural Kentucky.  Methods: Data 
were collected through an online survey of 115 PWID between 18-35 years old living in 
one of five rural counties. Logistic regression was used to identify predictors of seeking 
HCV care.   Results: A majority (83%) reported being screened for HCV of which 
approximately 66% reported testing positive. Of those testing positive, 60% reported 
seeking treatment, 8% reported receiving treatment, and 3% reported being cured. The 
PWID with self-reported HCV (n=63) in our sample were predominately Caucasian 
(98%) and male (62%). Participants who did not self-report recent injection drug were 
88% less likely to have sought HCV care (OR 0.12, p = 0.049). Recent opioid 
substitution therapy and transportation issues were important but non-significant factors 
(OR 5.002, p = 0.097; OR 3.169, p = 0.089, respectively); recent criminal history, 
homelessness, and being a caregiver were not predictors. Conclusion: The number of 
PWID who progressed through HCV care cascade was similar to other studies. Remote 
drug use placed people at an increased risk for not seeking HCV care. Additional 





3.1  Introduction 
Hepatitis C virus (HCV) disproportionately affects persons who inject drugs 
(PWID) with an estimated 30% of PWID between 18-30 years old infected with chronic 
HCV.1 HCV infection can easily be eradicated with treatment success rates approaching 
100%.2 In spite of advancements in antiviral therapy, the percentage of PWID who are 
cured remains low.3,4 Thus, it is crucial to enhance engagement in healthcare services 
among PWID.  
Successful treatment requires progression through a three step HCV care cascade: 
(1) screening, (2) linkage-to-care and (3) treatment uptake.4 Screening is the process 
whereby persons are tested for HCV antibodies and nucleic acid test (when appropriate) 
and made aware of his/her status.4 Linkage-to-care is the process by which people with 
HCV are evaluated by a practitioner experienced in the management and treatment of 
HCV (i.e. a hepatitis C specialist).4 Treatment uptake is the process of receiving 
treatment.4 However, successful treatment is rarely achieved, as most people are lost 
along the cascade of care. For example, in a large cross-sectional study of PWID, 89% 
were screened at least once in their lifetime with over half (57%) testing positive.3 An 
estimated 31% of those with an active infection were linked to care, 8% received 
treatment, and 3% were cured.3 The largest dropout occurred between diagnosis and 
linkage-to-care with a nearly 30% attrition rate occurring after diagnosis.3 Hence, it is 
essential to examine barriers to receiving treatment among PWID.  
Several barriers to linkage to HCV care have been identified at the patient level 
including on-going/recent drug use, being asymptomatic, and poor HCV knowledge. As 
an example, on-going or recent drug use is an important hindrance to being linked to 




or injecting drugs in the last 6 months were less likely to report being evaluated by a 
HCV specialist.5 In contrast, participants who had not injected drugs in the last six 
months were more likely to be linked to care. 6-7, 11 Moreover, being asymptomatic can 
also be a barrier to linkage-to-care. Participants in a qualitative study reported not having 
symptoms or feeling well as reasons for not seeking care.7 Others reported seeking HCV 
care when they experienced a decline in their physical health or developed symptoms, 
which they attributed to HCV.7 In addition, Hepatitis C virus knowledge can be a 
facilitator to HCV care. Patients who understand the potential severe consequences of 
remaining untreated are more likely to seek care.7-8 In contrast, a lack of knowledge about 
the diagnosis, the required workup, where to get treatment, and treatment availability can 
be deterrents to seeking care.7  
Moreover, additional patient barriers include fears and social circumstances. In 
previous studies, fear of treatment-related side-effects, liver biopsy, perceived low 
treatment efficacy, and/or having to self-inject medications were reported as barriers.7-8 In 
contrast, fear may serve as a motivator such that patients who witness friends becoming 
ill, requiring liver transplants or dying from HCV, report seeking HCV care.7,8 
Additionally, several social circumstances may pose significant barriers to HCV care 
among PWID. In an observational cohort study, participants were asked to complete a 
six-item questionnaire on social functioning (financial problems, conflict with partner, 
spouse, relatives or employer, and living with drug users).12 Lower social functioning 
scores were associated with lower likelihood of attending a scheduled consultation with 




custodial sentencing), employment obligations, family responsibilities, poor financial 
status, and chaotic lifestyles.10-11   
In addition to patient-level barriers, several system-level barriers exist in the 
literature. Participants in a qualitative study identified forgetting appointment dates/times, 
which they attributed to the extended length of time between making the appointment and 
the appointment date compounded by the lack of appointment reminders as barriers to 
attending their consultation appointment.7 Other barriers were lack of transportation, 
distance to nearest HCV specialist, and appointment times early in the day.10-11  It is 
important to examine such system level barriers to understand ways to mitigate their 
detrimental impact on HCV care among PWID.  
Clinical findings and provider-patient relationships are important facilitators to 
linkage to care. Elevated liver enzymes and/or a prior diagnosis of cirrhosis were 
associated with higher likelihood of attending initial consultation appointment.5,6  In a 
qualitative study, continuity of care, believing the provider was genuinely concerned 
about their well-being, and having trust and confidence in their provider were identified 
as important facilitators.7 Participants who felt that their provider was distant or felt 
stigmatized were less likely to seek care.7 Interactions with and responses of providers 
can have a meaningful impact on linkage-to-care.  
3.2 Purpose and Specific Aims 
Given the challenges that exist in enhancing care for PWID with HCV, it is 
important to further explore ways to improve their access to care. The majority of 
existing studies were conducted in urban areas and in countries with universal healthcare 




facilitators to linkage to HCV care among PWID who live in rural areas without universal 
healthcare where health disparities are greater. Thus, the purpose of this study was to 
describe progression through HCV care cascade and determine barriers and predictors of 
linkage to HCV care among rural PWID. The specific aims were to (1) determine 
differences in sociodemographic variables between those who did or did not seek HCV 
care; (2) describe progression through the HCV care cascade; (3) describe self-reported 
reasons for not seeking HCV care; and (4) determine which factors associated with 
linkage to HCV care in urban areas predict seeking HCV care in rural residents who 
inject drugs. 
3.3 Methods 
3.3.1 Sample and Setting 
The present study was a secondary analysis of data from a study to determine the 
utility of an online survey (about substance misuse and related risk behaviors) to screen 
and enroll a rural community of people who use drugs (PWUD). Initial participants were 
recruited via advertisements at community cookouts, use of flyers, and local study staff 
from outreach facilities. Additional PWUD were recruited using respondent-driving 
sampling. All participants were required to complete an online screening survey to 
confirm eligibility. Inclusion criteria were: self-reported use of opioids (prescription 
opioids, heroin, buprenorphine, methadone, and synthetic opioids) in the last thirty days 
to get high; living in one of five rural counties in Appalachia Kentucky; and between 18-
35 years of age. Eligibility was confirmed using date of birth to determine age and an 




A total of 249 participants met inclusion criteria and were enrolled between August 2017 
to July 2018.  Among the 115 PWID participants who reported a prior history of injection 
drug use, 63 reported screening positive for HCV in their lifetime and were included in 
the data analysis (Figure 1). 
3.3.2 Measures 
3.3.2.1 Sought HCV Care 
The primary outcome was linkage to HCV care defined as the process of being 
evaluated by a practitioner experienced in the management and treatment of HCV (i.e. a 
hepatitis C specialist).4 For this study, we operationally defined linkage-to-care as 
responding ‘yes’ to the question: “have you ever sought treatment for your hepatitis C 
infection?”   
3.3.2.2 Predictor Variables 
Predictor variables chosen based on literature review were: (1) child caregiver 
status: “Are you the primary caregiver for any children” (yes); (2) recent injection drug 
use: “I have not injected in the past 6 months” (yes); (3) transportation issues: “In the past 
6 months, have you been unable to do something that you needed to do because you did 
not have a way to get there?” (yes) (4) homelessness: “In the past 6 months, have you 
been homeless at any time?” defined as living on the street, or in a car, park, abandoned 
building, or shelter; (yes) and (5) criminal issues: “Check all that apply: in the past six 
months have you been in jail, prison, probation, parole, had a warrant out for your arrest 





Institutional Review Board approval was obtained at both study sites. All data 
were protected by a Federal Certificate of Confidentiality. Participants were provided the 
links to the screening survey, informed consent, and the main survey were posted on the 
study’s website hosted by WordPress. Those who completed the screening survey and 
met inclusion criteria, were directed to sign the informed consent prior to completing the 
survey.  De-identified data were kept in a safe location. 
3.3.4 Procedures 
Those who met inclusion/exclusion criteria were asked to complete the online 
survey that assessed rural risk environments; drug use patterns; human immunodeficiency 
virus (HIV) and HCV risks; the risk and occurrence of overdose; and use of at-home HIV 
testing. In addition to the standard survey questions, the participants who reported not 
seeking HCV care were asked to select (all that apply) from a list of predetermined 
reasons and/or fill-in-the-blank for additional reasons they had not sought care.  
3.3.5 Data Analyses 
Data were analyzed using SPSS Statistics 25. Specific Aim 1 was addressed by 
between groups comparisons using Chi Square. Descriptive statistics were calculated 
(means and standard deviations or frequency and percentages depending on level of 
measurement) to address Specific Aims 2 and 3. Univariate logistic regression were 
conducted to address Specific Aim 4 in which the following independent variables were 




transportation issues (4) homelessness and (5) criminal issues.  There was no 
multicollinearity identified among variables. Alpha was set a priori at 0.05 
3.4 Results 
3.4.1 Sample Characteristics  
The majority of the 63 HCV positive participants were Caucasian (98.4%), male 
(63.5%), and unemployed (66.7%). Almost 42% reported their highest level of education 
as a high school diploma or General Education Development (GED). There were no 
significant differences in gender, race, education, or employment status between 
participants who reported seeking HCV care and those who did not seek care.  
3.4.2 Progression through the HCV Care Cascade 
A total of 115 participants reported a lifetime history of injection drug use. As 
depicted in Figure 1, 83% of PWID reported being screened for HCV in their lifetime. Of 
those, 65% reported testing positive with 60% of those reporting seeking HCV care. 
However, only 8% of those who sought care reported receiving treatment and only 3% 
were cured.  
3.4.3 Self-Reported Barriers to Not Seeking Care 
Self-reported barriers are listed in Table 2. The most frequently selected barrier 
was could not afford care (25%) followed closely by not knowing where to go (22.2%) 
and not having insurance coverage (19.44%). Other barriers in decreasing order of 
frequency were not worried about HCV (13.89%), did not know treatment was available 




effects (5.56%). Ten participants provided self-generated barriers as follows: recent or 
ongoing drug use (11.11%), worried the doctor would not treat them (5.56%), being 
incarcerated (2.78%), being worried about side effects (2.78%), being worried it would 
be a waste of time (2.78%), and being recently diagnosed (2.78%). These reasons were 
not included in our analysis, as we did not have corresponding data for those who sought 
HCV care. 
3.4.4 Predictors of Seeking Hepatitis C Care 
People who self-reported they did not inject drugs in the last six months were 
88% less likely to report seeking HCV care (OR 0.12, 95% CI 0.015-0.994, p=0.049). 
Self-reported use of Opioid Substitution Therapy (i.e. methadone or Suboxone) in the last 
six months and not being able to do something in the last six months due to not having 
transportation (transportation issues) approached statistical significance (OR 5.002, 
0.748-33.446, p = 0.097; OR 3.169, 0.839-11.974, p = 0.089, respectively). Self-report of 
criminal issues, homelessness, and being the primary caregiver of a child in the last six 
months were not significant predictors of seeking HCV care. 
3.5 Discussion 
Progression through the HCV care cascade in our study was similar to the 
findings of an Australian study in which a comparable percentage of PWID were 
screened for HCV in their lifetime.3 However, only half as many PWID with HCV in 
their sample were linked to HCV care compared to our study. This is surprising because 
in contrast to the U.S., Australia has universal healthcare. We expected that fewer 




multiplayer healthcare system. It is possible that the difference between studies may be 
based on how we operationally defined linkage to care (have you ever sought treatment 
for HCV). In the Australian study, linkage to care was objectively measured as 
attendance to an HCV specialist. In contrast, we measured linkage to care as self-report 
of seeking care and therefore our findings are more vulnerable to self-report bias. 
Alternatively, our participants may have understood ‘sought treatment for HCV’ to mean 
seeing their PCP rather than seeing a HCV specialist. Despite differences in linkage to 
care rates in our study and the Australian study, there was a similarly low percentage of 
participants who received treatment and were cured. This suggests that a greater 
percentage of those linked to care in rural US did not receive treatment. This could be 
due to a difference in treatment eligibility between Australia and our sample or it could 
be that our sample faces more barriers to treatment uptake.   
Inconsistent with results from urban-dwelling populations,5-6, 11 recent injection 
drug use was a predictor of being linked to care. Our findings are interesting. Even 
though only six participants reported recent injection drug use, recent injection drug use 
predicted seeking HCV care. One reason for this difference could be the wording of the 
question; participants were asked to select all that apply with no recent injection drug use 
defined as, “I have not injected drugs in the last 6 months.” Perhaps they were confused 
by this statement. Moreover, perhaps our study differs from the total rural-dwelling 
PWID population in that they have better resources which allow them to be linked to care 
despite recent drug use.  Using Suboxone or methadone therapy have also been identified 




This difference may be due to our smaller sample size. Future studies with more robust 
samples should further explore this relationship.   
Consistent with our predictions and similar to a prior study,7 a large portion of 
participants in our study reported not knowing there was treatment for HCV and/or not 
knowing where to get treatment as barriers to seeking care. This is not surprising as 
PWID residing in rural Kentucky may often need to cross county lines to receive HCV-
specialty care. This further illustrates the importance of providing education about 
treatment availability/accessibility to all PWID.  
Fear of side-effects was commonly reported as a barrier in prior studies.7-8 One 
reason it was not common in our study may be related to the time of data collection. In 
prior studies, data were collected when PEGylated interferon (well-known for its severe 
side effects) was frequently used, while our data were collected in the era of direct acting 
antiviral therapy, which has fewer side effects. 
Not surprisingly, social circumstances such as legal issues, homelessness, and 
family responsibilities have been reported as barriers to linkage to care elsewhere.10-12 
One possible reason why our findings differed is that our sample size was rather small. It 
could also be that other non-measured social circumstances have a greater influence on 
linkage-to-care in people living in rural areas. Thus, future qualitative studies may be 
warranted to examine social circumstances that influence linkage to care among rural 
PWID. 
Because transportation was named a barrier to HCV treatment among urban-
dwelling PWID,10 we expected transportation to be a significant barrier. Rural areas may 




access to reliable vehicles and/or gas money. However, transportation issues were not a 
significant predictor of seeking HCV care in our study, although it did approach 
significance and was self-reported as a reason for not seeking care by a few participants. 
It is possible that with a larger sample it would be a predictor for rural residents.    
Cost or financial burden was only reported in one prior study as a barrier to 
linkage to care.10 Cost and lack of insurance accounted for a large percentage of 
participants who did not seek care in our study. Not surprising, this is most likely due to 
prior studies being conducted in a country with universal healthcare versus a country with 
a multi-payer healthcare system.5-8, 10-12 Hence, practitioners should make an effort to help 
PWID navigate the costs associated with healthcare. 
3.5.1 Limitations 
This study is among the first to provide data about barriers to seeking HCV care 
among rural inhabitants in the U.S, a country without universal healthcare.  However, a 
few limitations are noted. First, our study may be underpowered due to our small sample 
size. Second, our study was a secondary data analysis and is therefore limited to the data 
collected. Therefore, we were not able to determine if factors that were important in 
existing literature such as fear of treatment side-effects and invasiveness, HCV-
knowledge, and being a/symptomatic are predictors of linkage to care in this population. 
In addition, we were not able to assess any provider-level barriers.  It is possible that 
variables not measured in our study are important predictors of linkage-to-care in this 
population. Third, participants were asked to take part in a very lengthy survey. Longer 




questions towards the end of the survey are answered at a faster rate and in a more 
uniform manner which brings to question the quality of responses.13  
Fourth, participants were required to have functional literacy and basic computer skills to 
complete the required online survey. It is reported that an estimated 30% of the 
Appalachian population are functionally illterate14 and internet access is limited.15 
Caution should be used in extending these findings to those with limited literacy and/or 
no internet access. Lastly, as with most behavioral studies, our variables were self-report 
measures and subject to social desirability and recall-bias. To minimize social-
desirability, participants were made aware that their data would be kept confidential and 
de-identified during the consenting process. In addition, surveys were self-administered 
which has clearly demonstrated a reduction in social desirability bias.16  
3.6 Conclusions 
Our findings suggest that barriers and facilitators associated with linkage-to-care 
of rural inhabitants with limited access to health care are similar to barriers and 
facilitators in urban areas and in countries with universal health care. Additional research 
is needed to confirm these findings using a larger sample as well as provider-level and 
system-level barriers to HCV care. Findings from these studies can then guide 
interventions aimed at increasing linkage-to-care, treatment uptake, and ultimately 





Table 3.1 A comparison of sociodemographic variables of rural participants who did and 











Gender     0.17 
   Male 40 (63.5) 27 (67.5)  13 (32.5)  
   Female 23 (36.5) 11 (50)  12 (50)  
Race*      
   Caucasian 62 (98.4) 37 (97.3)  25 (100)  
   African American 1 (1.6) 1 (2.6)  0 (0)  
Education     0.94 
   Less than high school 21 (32.8) 12 (57.1)  9 (42.9)  
   High school/GED 26 (42.9) 16 (42.1)  10 (40)  
   Some college or 
   technical school 
15 (323.8) 8 (21.1)  6 (24)  
Employment     0.48 
   Employed 21 (33.3) 13 (32.2)  8 (32)  
   Unemployed 42 (66.7) 25 (65.8)  17 (68)  
*Chi square not run due to small sample size. Values are n (%).   





Table 3.2 Self-reported reasons for not seeking HCV care among rural residents who 
inject drugs  
Reasons Number of participants*  
n (%) 
Could not afford it 9 (25) 
Did not know where to go 8 (22.2) 
Did not have insurance coverage 7 (19.4) 
Not worried about HCV 5 (13.9) 
Recent drug use 4 (11.1) 
Did not know treatment was available 4 (11.1) 
Worried about side effects 3 (8.3) 
Did not have transportation 3 8.3) 
Worried MD would not treat them 2 (5.6) 
Incarcerated 1 (2.8) 
Worried it would be a waste of time 1 (2.8) 
Recently diagnosed  1 (2.8) 







Table 3.3 Predictors of Seeking Hepatitis C Virus Care among Rural Residelnts Who Inject 
Drugs (n= 63) 
 Odds Ratio (95% CI) P-value 
Primary caregiver of a child  0.803 (0.167-3.854) 0.784 
No recent injection drug use  0.121 (0.015-0.994) 0.049 
Had recent suboxone or 
methadone use  
5.002 (0.748-33.446) 0.097 
Had transportation issues  3.169 (0.839-11.974) 0.089 
Had recent criminal issues  0.763 (0.229-2.54) 0.659 






Figure 3.1 Progression Through the Hepatitis C Virus Care Cascade among Rural-
dwelling People Who Inject Drugs 
 
  
Reported history of 
injection drug use 
46.2% (115/249)
Screened for HCV: 
83.4% (96/115)
Tested positive for 
HCV antibodies 
65.6% (63/96)
Sought HCV care: 
60.3% (38/63)
HCV treated: 7.9% 
(5/63)






CHAPTER 4. PREDICTORS OF PRIMARY CARE USE AMONG FEMALE 
INMATES WHO INJECT DRUGS LIVING IN RURAL APPALACHIA 
Abstract 
Hepatitis C virus (HCV) infection is a growing epidemic with highest prevalence 
among people who inject drugs (PWID) especially those in rural Appalachia and inmates. 
To receive HCV treatment, one must be screened and referred to a HCV specialist. 
Primary care providers (PCPs) are ideally situated to provide these services. However, 
PWID are at an increased risk for contracting HCV but are less likely to access PCPs. 
Factors associated with accessing a PCP include being female and employed while low 
socioeconomic status, daily injection drug use, illegal income, and chronic homelessness 
have been identified as barriers. Few studies have evaluated vulnerable subpopulations of 
PWID such as those living in rural communities or inmates PURPOSE: To identify 
predictors of PCP use among incarcerated female PWID living in rural Appalachia.  
METHODS: This was a secondary analysis of data from 302 incarcerated female PWID 
from a larger randomized control trial. Multivariate logistic regression was used to 
determine predictors of primary care use. RESULTS: The majority (55%) of the sample 
had less than a high school education, were single (35.7%) and were unemployed (74.5%) 
with an average age of 32 (+/-7.92) years. Age (OR 1.05, CI 1.01-1.09, p = 0.01) and 
reporting a lack of insurance as a barrier to seeking healthcare (OR 1.95, CI 1.12-3.4, p = 
0.02) were significant predictors of PCP use. CONCLUSIONS: Knowing that younger, 
rural-dwelling female inmates with a history of injecting drugs are more likely to not use 
PCP services- clinicians should use opportunities such as emergency departments, jails, 






People who inject drugs (PWID) are at the highest risk for contracting HCV, a 
blood-borne viral infection affecting 2.4 million people in the United states.1 As the 
opioid crisis continues to grow, so do acute cases of hepatitis C virus (HCV) infection. In 
fact, acute cases of HCV infection have been on the rise since 2004, coinciding with the 
opioid epidemic and increasing rates of injection drug use.2 A recent analysis of several 
national data bases indicates a steady rise in HCV cases across the nation, with the largest 
seen east of the Mississippi River.3 This is even more pronounced in Appalachian states 
(Tennessee, West Virginia, Virginia, Kentucky) where the incidence of acute HCV 
infections increased by 45% from 2006-2012 among people less than 30 years old with 
approximately 75% reporting injection drug use as their primary risk factor.3   
Naturally, inmates are another at-risk group since a history of drug use is common 
among inmates.23 In fact, incarcerated persons have 2-10 times higher prevalence of HCV 
infections than the general population with an estimated 29% of incarcerated persons in 
North America testing positive for HCV antibodies (indicating prior exposure to the 
virus). 4 This is more pronounced among female inmates. Forty to fifty percent of female 
inmates have chronic HCV infections; that is a 20 times higher rate of infection than the 
general population.6 In addition, a staggering 33% of Americans infected with HCV will 
enter into a correctional facility each year.28  
Rates of infection are highest among rural female inmates with a history of 
injecting drugs however cure rates remain low. This low cure rate is owed to a not being 




situated to facilitate progression through the HCV care cascade. In fact, visiting a PCP is 
associated with lower risk of HCV infection, increased likelihood of being screened, 
increased awareness of HCV status, and increased likelihood of being linked to a 
specialist.8-10 However, PWID, often underutilize PCP services.9 This is even more 
pronounced in female inmates.5, 11An estimated one third of PWID reported visiting a 
PCP within the last month.13-14 However, only one third of female inmates reported 
seeing a PCP when acutely ill in the last year11 and only half who reported a chronic 
illness saw a PCP in the 12 months prior to incarceration.12  
Upon release many inmates return to a community with limited access to 
healthcare (i.e. rural areas) and endure disruptions in treatment for mental health, medical 
conditions, medications, and substance use disorders.24-27 Moreover, most inmates lack 
health insurance upon release and if they had Medicaid benefits prior to incarceration, 
those benefits have since been terminated leaving them in a vulnerable position.28 
Therefore, rural female inmates represent a vulnerable, unreached group of PWID that 
are at an increased risk for contracting HCV but unlikely to receive the appropriate 
medical care and needed follow-through. 
4.1.1 Primary Care Utilization among People Who Inject Drugs 
Factors associated with a significantly higher likelihood of seeing a PCP within 
the last month include: being female, employed, living with children, and recent contact 
with social/welfare worker.14 Low socioeconomic status (monthly income less than 
$400), daily injection drug use, illegal or semi-illegal income, and chronic homelessness 




PWID self- reported barriers to healthcare access include the burden of 
appointments, lack of transportation, negative staff attitudes, and fear of receiving bad 
news pertaining to their health.15 The impact of these barriers on accessing healthcare 
appeared to be contingent on the attitudes of healthcare professionals, the circumstances 
and needs of the PWID, the availability of alternative services, and the frequency of 
needed care.15 Self-reported facilitators of healthcare utilization included trust in 
physician, presence of health insurance, supportive relationships (e.g., familial), personal 
circumstances/life events (e.g., becoming a parent), and the individual’s state of mind 
(i.e., feeling motivated and positive).16-17 
4.1.2 Anderson’s Behavioral Model of Health Services Use 
Utilization of healthcare services is a complex interaction between individual, 
environmental, and healthcare characteristics.18 Andersen developed the Behavioral 
Model of Health Services Use (Figure 1) to explain this dynamic relationship.18 Andersen 
proposed use of health services was a result of the interaction of predisposing factors, 
potential enabling resources, and need or current level of illness.18  Predisposing factors 
are comprised of demographics, social structure, and health beliefs.18 Demographics 
include age, gender, and ethnicity whereas social structure includes educational level and 
social class.18 Health beliefs are values, attitudes, or knowledge about health and health 
services that may influence perceived need and use of health services.18 Enabling 
resources, include personal, family, and community factors that facilitate the use of 
health services such as income, health insurance status, and distance traveled.18 Need is 
divided into perceived and evaluated where perceived need is one’s perception of his/her 




assessment of one’s health status and the need for health care.18 Anderson’s model will 
serve as the framework for this study. 
4.2 Specific Aims 
The specific aims were (1) to identify independent predictors of primary care use 
(defined as having one healthcare facility usually attended prior to incarceration) from 
predisposing factors (age, marital status, highest educational achievement, employment 
status, worried about health in the past 12 months, perceived chance of getting HCV), 
potential enabling factors (insurance coverage, total family 6 month income, too far to 
go), and healthcare needs (health problems interfered with responsibilities, perceived 
health); and (2) to determine whether primary care use is a predictor of positive HCV 
antibody. 
4.3 Methods 
4.3.1 Design, Setting, and Participants 
This was a secondary analysis of data from 384 participants in a randomized 
clinical trial (NIH/NIDA 1R01-DA033866) to determine changes in high-risk behaviors 
and health service utilization in response to traditional education versus motivational 
interviewing. Data were collected from drug-using rural women from county jails who 
were at high-risk for HIV and HCV. Inclusion criteria were: 1) National Institute on Drug 
Abuse-modified Alcohol, Smoking and Substance Involvement Screening Test score of 
four or greater (moderate to high drug use); 2) engagement in at least one sex risk 
behavior in the past three months; 3) willingness to participate in brief intervention 




prior history of injection drug use. Participants were excluded if they had a documented 
mental illness or cognitive impairment.  
4.3.2 Procedures 
The parent study was approved by the Institutional Review Board and a Federal 
Certificate of Confidentiality was obtained. Participants were enrolled in the larger study 
trial and completed baseline interviews before being randomly assigned to one of two 
conditions- HIV Education or Motivation Interviewing. Only baseline data were used for 
this secondary analysis.  
4.3.3 Measures 
The primary outcome for this secondary analysis was PCP use. PCP use falls under 
the umbrella of healthcare utilization- defined as the description of the use of services by 
persons for prevention, maintenance or cure of health problems, and for overall well-
being.19 Self-report measures of health care use (e.g. hospital and office visits) have 
moderate to high agreement with administrative health care claims, especially pertaining 
to office visits.20 Agreement between the two are highest when evaluated via internet-
surveys.21 We therefore, operationally defined primary care use as participants’ self-
report of having a clinic/health center/doctor’s office/other facility that they usually 
attended prior to incarceration.  
4.3.3.1 Predisposing Factors 
The predictor variables for this secondary analysis were based on Andersen’s Model 
of Health Care Use and on review of the literature (Figures 1 and 2).18 Age (in years) was 




therefore, ethnicity and gender were not included. Social structure was operationally 
defined as highest level of education (less than high school, high school, or some higher 
education) and employment status (employed/unemployed). Health beliefs were 
measured as being worried about health in the past 12 months (yes) and perceived chance 
of getting HCV (less than 50%). 
4.3.3.2 Enabling Factors 
For this analysis, we used income, health insurance status, and travel distance as 
enabling factors. Income was measured based on total income 6 months prior to 
incarceration in U.S dollars, health insurance status was measured as “was no health 
insurance a barrier to seeking needed healthcare services?” (yes), and travel distance was 
measured as “was it too far to go a barrier to seeking needed healthcare services?” (yes). 
4.3.3.3 Perceived Need 
Perceived need was measured as “have health problems kept you from meeting 
responsibilities at work, school or home?” (yes) and perceived health in last 12 months 
(fair to poor).  
4.3.3.4 Hepatitis C Virus Antibody Testing 
Hepatitis C Virus antibody testing was performed using OraQUICK ADVANCE® 
Rapid HCV Antibody Test kits, which have demonstrated sensitivity (95.5-100%) and 




4.3.4 Statistical Analyses  
Data were analyzed using SPSS 25.0 with an alpha set at 0.05. Independent t tests 
were calculated for continuous variables and Chi square for categorical variables to 
compare those who reported primary care use with those who did not. Multivariate logistic 
regression was run to address Specific Aim 1 in which the following independent 
variables were forced entered in one step: (1) age, (2) highest level of education, (3) 
employment status, (4) being worried about one’s health, (5) perceived chance of getting 
HCV, (6) six-month income, (7) insurance status, (8) travel distance, (9) perceived need, 
(10) perceived health. Univariate logistic regression was run to address Specific Aim 2; 
determine whether HCV antibody status predicts being in the group that reported use of a 
PCP prior to incarceration.  
No assumptions were violated in either logistic regression model. The assumption 
of a linear relationship between age and income and the logit transformation of the 
dependent variable (having one healthcare facility that they usually visited) was tested and 
found to not be violated. There was no multicollinearity or significant outliers/influential 
points. 
4.3.5 Results 
Our analysis included a total of 302 PWID (Table 1). All participants were 
Caucasian females. The majority (55%) had not graduated high school, were single 
(35.7%), and were unemployed (74.5%). On average, our sample was approximately 32(+/- 
7.4) years of age and had a total average income of $9,222.05 (+/- 20,855.41) six months 




prior to incarceration. Those who reported PCP use were significantly older (33 +/- 7.9 vs. 
30 +/-6.4 years, p = 0.01). 
Our multivariate logistic regression model is presented in Table 2. The model was 
significant (p = 0.01). Age was the only predisposing factor to predict primary care use. 
Participants were 5% more likely to use healthcare for each additional year of age (OR 
1.05, CI 1.01-1.09, p = 0.01). Income as a continuous variable was highly variable and 
therefore not included in the regression model. Interestingly, participants who reported that 
a lack of insurance was not a barrier to healthcare were 95% more likely to engage in 
primary care services (OR 1.95, CI 1.12-3.4, p = 0.02). The remaining enabling factors 
were not predictors of primary care use. Reporting health problems that interfered with 
responsibilities was a significant need factor. Those who reported having health problems 
that interfered with other responsibilities in the last 12 months were about 40% more likely 
to have engaged in primary care services (OR 0.60, CI 0.33-1.07, p = 0.08).  
 Results from our univariate logistic regression model are presented in Table 3. 
HCV antibody status (positive versus negative) was not a predictor of primary care use.  
4.4 Discussion 
In alignment with Anderson’s Model, we found that age and lack of insurance 
were barriers to PCP use. A lack of insurance as a barrier to accessing needed healthcare 
was the single most important predictor of not seeing a PCP. This is alarming in a group 
of women who will upon release face limited access to healthcare services, lack of or 
suspension of health insurance and disruption in continuity of healthcare.24-28  
Inconsistent with his model, employment status, marital status, chance of getting 




responsibilities, distance traveled, and perceived health were not predictors of primary 
care use. One reason for this difference, could be that this vulnerable population faces 
numerous barriers to care and this model did not account for the additive effects of 
multiple barriers.  
Contrary to prior studies among PWID13-14, employment status was not a 
predictor of primary care use. This difference may be due to the majority of our sample 
being unemployed and therefore employed females were underrepresented in our sample.  
In prior studies, transportation issues were a barrier to healthcare utilization15 
however, we found that distance traveled was not a significant barrier. This could be 
related to how we measured this barrier. We operationalized transportation issues as, ‘is 
distance a barrier to healthcare use”. Perhaps lack of a reliable vehicle or gas money 
rather than distanced traveled contributed to difficulty with transportation. Or perhaps, 
they were incarcerated at the time of needed healthcare services and transportation alone 
was not the hindering factor. Moreover, asking our participants to be introspective and 
determine if distance is a barrier may produce different results as opposed to evaluating 
associations between distance traveled and PCP use.  
4.4.1 Limitations 
Our study has some limitations that warrant consideration. First, we used an 
indirect measure of primary care use rather than administrative healthcare claims. There 
is considerable data that supports the reliability of self-report measures of healthcare use. 
However, there are numerous ways to ask patients about use of primary care services. 
Depending on how this is operationalized, it could render different findings. Because this 




barriers/facilitators. Therefore, it is possible that other factors are influential in PCP use. 
While our sample size of 302, was acceptable, our sample size restricted the number of 
predictor variables we could use in our model. Last, are data were primarily self-report 
measures. Self-report measures are vulnerable to social desirability bias in which the 
participants may answer in the most favorable way.  Self-report measures are also 
susceptible to recall bias.  
4.5 Conclusions 
Our findings suggest only two predictors of PCP use among this vulnerable 
population. Additional research is needed to find other predictors of PCP use among 
rural-dwelling female inmates with a history of injecting drugs. Special attention should 
be given to examining provider level barriers as well as the additive effects of multiple 
potential barriers in this population.  
In the meantime, our findings can be applied at the clinical and policy level. 
PWID can be very transient (frequently relocating, changing phone numbers, etc.) but 
while incarcerated they remain in a fixed location and therefore are an ideal target for 
interventions. Specifically, jail staff could offer information about Medicaid eligibility 
after release. This responsibility extends beyond jail staff to healthcare personnel who 
should provide at-risk individuals (i.e. those who are underinsured or uninsured and 
young PWID) with information on local facilities that offer sliding-scale/income-based 
payment plans. Clinicians should also use alternative contacts such as emergency 
departments, jails, prisons, urgent treatment centers, and addiction clinics to screen for 
HCV and refer to specialists. On a policy level, greater access to affordable insurance is a 




Table 4.1 Comparison of socio-demographic variables of people who inject drugs and 
used primary care services with those who did not  
 Total (n=302) No regular 
healthcare 
facility, n=127  
Regular 
healthcare 
facility, n=175       
P-Value 
Age (Years)  31.6+/-7.5 29.9+/-6.4 32.9+/-7.9 0.01 
Total income 
in 6 months 
before 
incarceration  
9222 ± 20855 8268 ± 17026 9908 ± 23249 0.48 
Highest level 
of education  
   0.37 
Less than high 
school 
154(50.1) 70(55) 84(48)  
Completed 
high school 
88(29.14) 36(28.3) 52(29.7)  
Some higher 
education 
60(19.9) 21(16.5) 39(22.3)  
Marital Status:     0.01 
Married 95(31.5) 37(29.1) 58(33.1)  




99(32.7) 33(25.6) 66(37.8)  
Employment 
Status:   
   0.32 
Employed  63(20.9) 23(18.1) 40(22.9)  






Table 4.2 Predictors of Primary Care use among Female Inmates with a History of Injecting 
Drugs Living in Rural Appalachia 
 Odds Ratio 95% Confidence 
Intervals 
P value 
Omnibus model Χ2 = 36.998, df 13, p <0.001 
Age (Years) 1.05 1.01-1.09 0.01 
Employment status 6 months 
    Unemployed Reference 
    Employed 1.8 0.95-3.41 0.07 
Highest level of education 
    Some higher   
    Education 
 
Reference 
    High School 0.62 0.31-1.22 0.16 
    Less than high   
   School 
 
0.81 0.39-1.67 0.56 
Marital status 
    Separated,  
    divorced, 
widowed 
Reference  
    Not Married 0.99 0.52-1.87 0.97 
    Married 0.59 0.32-1.11 0.11 
Perceived chances of getting Hepatitis C 
    High (75-100%) Reference 
    Small to 
Moderate   
    (0- 50%) 
0.8 0.47-1.35 0.40 
Worried about health/behaviors during past 12 months  
    Yes  Reference 





Table 4.2 (Continued) 
No insurance coverage a barrier seeking needed health care services 
    Yes Reference 
    No  1.95 1.12-3.4 0.02 
Distance a barrier to seeking needed health care services 
    Yes Reference 
    No 1.09 0.61-1.97 0.77 
Had health problems that prevented meeting responsibilities at work, school or home 
during past 12 months 
    Yes Reference 
     No 0.596 0.33-1.07 0.08 
Perceived health in last 12 months  
    Good to Excellent Reference 







Table 4.3 Hepatitis C antibody status as a predictor of primary care use (n= 277) 
 Odds ratio 95% confidence 
intervals 
P value 
Hepatitis C antibody status    
               Positive    Reference   

































CHAPTER 5. CONCLUSIONS 
5.1 Background and Purpose 
Untreated hepatitis C can have grave consequences.1 Fortunately, HCV can be 
cured with direct acting antiviral therapy.2 PWID and inmates are among those with the 
highest incidence of HCV but cure rates in these populations remains low.3-6 Inadequate 
screening and linkage to care remain among the largest impediments to successful 
treatment.2  
The purpose of this dissertation was to develop a broader understanding of the 
barriers and facilitators to healthcare utilization among rural-dwelling People Who Inject 
Drugs (PWID) at the primary care level, where screening for hepatitis C virus (HCV) 
may take place and at the specialist level (linkage to care). The following three 
manuscripts addressed important gaps in knowledge: (1) a review of the literature to 
describe the state of science on linkage to care among PWID, (2) a cross-sectional study 
to determine whether predictors of linkage to care identified in urban-dwelling PWID 
from countries with universal healthcare predicted seeking HCV care among PWID 
living in rural Appalachia, and (3) a cross-sectional study to determine predictors of 
primary care provider (PCP) use among female inmates living in rural Appalachia with a 
history of injecting drugs.  
This chapter will summarize the findings of this dissertation with the intention of 
advancing the state of science on healthcare use (primary care and specialist care) among 
rural-dwelling PWID. This chapter will also provide recommendations for clinical 




5.2 Summary of Findings 
Chapter Two is a review of the literature on the current state of science on linkage 
to HCV care among PWID.  We reviewed a total of seven studies, two of which were 
qualitative, four were quantitative and one was mixed methods. Four studies were 
conducted in Australia, two in Ireland and one in Greece. In all seven studies, patients 
were recruited from addiction-based clinics or community service facilities. Only two 
studies were conducted after direct acting antiviral therapy became standard of care. 
Barriers to linkage-to-care at the patient-level included: ongoing substance use, limited 
knowledge about HCV, competing priorities, and being asymptomatic. Distance traveled, 
lack of transportation, and early appointment times were reported as system-level 
barriers. Facilitators at the provider-level included elevated liver enzymes, diagnosis of 
cirrhosis, and a trusting patient-provider relationship. 
 Chapter Three is a cross-sectional study in which we examine predictors of 
seeking HCV care among rural-dwelling PWID. Our final analysis included sixty-three 
HCV positive PWID. Inconsistent with prior studies,7-9 recent injection drug use was a 
(and the only) predictor of seeking HCV care. Self-reported use of Opioid Substitution 
Therapy in the last six months and transportation issues seemed to be important but were 
not statistically significant. Inconsistent with existing literature12-13 self-report of criminal 
issues, homelessness, and being the primary caregiver of a child in the last six months 
were not predictors of seeking HCV care. The following were the most commonly self-
reported barriers provided by HCV positive PWID who did not seek care: could not 
afford care (n= 9), did not know where to go (n= 8), no insurance coverage (n = 7), not 
worried about HCV (n = 5), did not know treatment was available (n = 4), recent or 




treatment side effects (n =3) and are consistent with prior findings.10-12 Our findings 
suggest some differences between barriers/facilitators to seeking HCV care among rural 
and urban dwelling PWID. 
 Chapter Four is a cross-sectional study to determine predictors of PCP use among 
rural-dwelling inmates with a history of injecting drugs. Our analysis included a total of 
302 participants. Age and no insurance issues were significant predictors of primary care 
use. Participants were 5% more likely to use healthcare per each additional year of age and 
participants who reported a lack of insurance was not a barrier to healthcare were 95% 
more likely to engage in primary care services. Our results suggest that there are 
differences between rural-dwelling female inmates with a history of injecting drugs 
compared to their non-incarcerated urban counterparts.   
5.3 Impact of Dissertation on the State of Science 
This dissertation has advanced the state of science on the predictors of primary care 
use and linkage to care among vulnerable populations (rural-dwelling, female inmates) by 
(1) identifying gaps in the literature, (2) describing predictors and self-reported barriers to 
seeking HCV care among rural-dwelling PWID after the advent of direct acting antiviral 
therapy, and (3) determining predictors of PCP use among rural-dwelling female inmates 
with a history of injecting drugs.  
 Chapter Two revealed several gaps in the literature on predictors of linkage to 
care. First, there is an overall lack of knowledge about barriers and facilitators of linkage 
to care among PWID with only seven studies meeting inclusion criteria. Nearly 40% of 
the reviewed studies were qualitative data and only one study examined longitudinal 




Researchers in only one study recruited participants from rural areas 11; all others 
recruited participants from urban cities and countries with universal healthcare. In 
addition, participants for all studies were recruited from community health centers, 
needle exchange programs or addiction treatment facilities, often with onsite HCV 
treatment available. This demonstrates a lack of real-world data. Third, only two studies 9, 
12 were conducted after direct-acting antiviral (DAA) therapy became standard of care 
and therefore, it remains unclear if fear of side effects is still important.  Lastly, linkage to 
care was operationally defined differently in each study and likely attributes to 
inconsistent findings in the literature.   
Chapter Three broadened our understanding of barriers and facilitators to seeking 
HCV care among PWID by providing insights on barriers/facilitators faced by rural 
PWID. Specifically, our findings illuminate key differences between urban PWID from 
countries with universal healthcare in a Pre-DAA era and rural PWID from countries 
with a multi-payer healthcare system in a post-DAA era. We found three key differences. 
First, our sample of recent injection drug users were more likely to be linked to care. 
Second, consistent with our expectations, fear of side-effects related to HCV treatment 
are much less relevant in the post-DAA era. Lastly, our findings suggest that cost 
associated with healthcare and lack of insurance are very important barriers for rural 
PWID in countries without universal healthcare.  
 Chapter Four represents to our knowledge, the only study to examine predictors 
of PCP use among rural, female inmates with a history of injecting drugs. The results 
illustrate the need to improve insurance access to this vulnerable population. In addition, 




5.4 Recommendations for Clinical Practice and Research 
We conducted one study to address one of the gaps identified in Chapter 2, but 
additional research is needed to confirm these findings and expand the existing 
knowledge base. Specifically, longitudinal data and more real-world data are needed that 
focuse on vulnerable populations with high rates of infections such as those residing in 
rural areas, jails, prisons, etc. Ideally, a large study should be conducted following rural 
PWID from time of diagnosis and over several years to determine predictors of linkage to 
care. More current research is also needed in the new DAA treatment era to determine if 
fear of side effects or concerns about the ineffectiveness of treatment is still relevant. 
Lastly, consistency should be used in how linkage to care is defined.  In the interim, 
caution should be used in generalizing these findings to real-world populations.  
Findings from Chapter Three suggest that while there are similarities in barriers 
and facilitators associated with to linkage-to-care in rural inhabitants, there are also some 
key differences. Additional research is needed to confirm these differences using a larger 
sample size of rural PWID. In addition, future studies should attempt to obtain more 
objective predictor variables as opposed to relying exclusively on self-report measures. 
Future research is also needed to determine system-level and provider-level barriers 
among vulnerable populations such as PWID.  
In Chapter Four, we found that younger age and no insurance were barriers to 
PCP use among female inmates with a history of injection drugs.  Knowing this, 
clinicians should target this vulnerable group and seek out opportunities to screen and 
refer to specialist. For example, when clinicians encounter young and/or uninsured PWID 




they should offer information about free screening sites or treatment facilities that offer 
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